Skip to page content

Drug Markets and Supply

Featured

Q&A
A New Approach to Fighting Synthetic Opioids: Q&A with David Luckey and Jayme Fuglesten
The opioid crisis isn't just about drug policy or law. It involves national security, homeland security, intelligence, diplomacy, supply chain issues, and cryptocurrency. Drawing on RAND's expertise across all those areas, the Commission on Combating Synthetic Opioid Trafficking delivered a plan, a call to action about what it's going to take to save lives.
Apr 26, 2022
Commentary
Fentanyl Makes an Already Dangerous Drug Market Deadlier Than Ever
Failure to recognize and respond to how rapidly illegal drug markets have changed with the arrival of illegally manufactured synthetic opioids will continue to put many Americans at risk of exposure to fentanyl, endangering the lives of hundreds of thousands more for years to come.
May 2, 2022

Explore Drug Markets and Supply

Commentary
State and Local Policy Is Changing for Psychedelics. What Will the Feds Do?
Psychedelics are attracting interest as a treatment for some mental health conditions. In response, some states and cities are changing their laws and policies on the supply and use of these mind-altering substances. But like cannabis, most psychedelics are federally prohibited—raising some tough questions for the federal government.
Jun 12, 2023
Report
Onderzoek Experiment Gesloten Coffeeshopketen: Rapportage voormeting 2021: [Study in support of the Controlled Cannabis Supply Chain Experiment: Pre-measurement report 2021]
The document reports on cannabis consumption, the sale of cannabis from tolerated dispensaries (coffeeshops) and the illegal sale of hash and weed in the Netherlands prior to the introduction of an experiment with a legal cannabis supply chain.
May 31, 2023
Project
Opioids Uncharted: Mapping America's Opioid Crisis
A RAND initiative to map the underexplored consequences of America's opioid crisis—and discover big-picture solutions.
Mar 21, 2023
Report
Inzichten in de effectiviteit van preventieve instrumenten in de strijd tegen georganiseerde criminaliteit: [Insights into the effectiveness of preventive instruments tackling organised crime]
This study responds to a call from the Dutch Research and Documentation Centre to gather insights into the effectiveness of preventative instruments in the field of organised crime, drawing on a review of the literature and expert interviews.
Jan 31, 2023
Journal Article
The Kids Aren't Alright: The Effects of Medical Marijuana Market Size on Adolescents
Combining a novel measure of market size with two shocks to U.S. federal enforcement policy, researchers find that legal medical market growth increases youth cannabis use and alcohol-involved car accidents, suggesting complementarities for youths. It’s unclear whether these results apply to cannabis legalization for nonmedical purposes.
Dec 9, 2022
Commentary
Cannabis Legalization in Europe: Planning Ahead
Since 2012, multiple jurisdictions have changed their laws to legalize the production, possession, and use of cannabis for nonmedical purposes. While most of these changes took place in the Americas, there are signs that the European legal landscape might be changing, too.
Nov 9, 2022
Commentary
What's Next After Biden's Announcement on Cannabis and Racial Equity?
Cannabis legalization isn't just a yes-or-no choice. There are many ways for state and federal policymakers to shape the market and tax it. With deliberations in Washington, D.C., beginning and more states set to vote on the issue in November, now is the time for lawmakers to take stock of how potential changes will or won't help communities of color.
Oct 11, 2022
Multimedia
What Policy Changes Could Help Save Lives from Illicit Synthetic Opioids Overdose?
In this recording of a July 2022 virtual event, experts discuss findings from the final report by the Commission on Combating Synthetic Opioid Trafficking, and recommendations to reduce the number of lives lost to illicit synthetic opioids.
Aug 18, 2022
Journal Article
How Much Illegally Manufactured Fentanyl Could the U.S. Be Consuming?
This article provides guidance through two thought experiments that provide a hypothetical upper bound on U.S. consumption of fentanyl.
Jul 28, 2022
Journal Article
Rapid Changes in Illegally Manufactured Fentanyl Products and Prices in the United States
This analysis used data from drug seizures and undercover purchases to address two questions: To what extent does supply of illegally manufactured fentanyl (IMF) vary over time and geography? What has happened to the purity-adjusted price of IMF?
May 13, 2022
Periodical
RAND Review: May-June 2022
The cover story explores what prison-based programs are available to help incarcerated parents and their children. Another feature examines ways to help social media users navigate the online extremist ecosystem.
May 11, 2022
Commentary
A Greater Focus On Harm Reduction Will Save Lives
For decades, elected officials brushed off harm reduction as a viable option for reducing the harms of drug use over concerns of enabling drug consumption. But now, these strategies are front and center, spoken aloud, from the largest podium in the land, and during prime time. What caused this historic about-face?
Apr 29, 2022
Commentary
A New and More Dangerous Drug Market Requires a New Approach
Synthetic opioids are likely to increasingly reach illegal drug markets. Failure to recognize and respond to how rapidly drug markets have changed with the arrival of illegally manufactured synthetic opioids will continue to put many at risk of exposure to fentanyl, endangering the lives of hundreds of thousands more Americans for years to come.
Mar 16, 2022
Report
An Overview of the Effectiveness of U.S. Counternarcotics Efforts in Colombia, 2000–Present, and Recommendations for the Future
The authors of this report examine the period in Colombia from 2000 to 2020 to assess the effectiveness of U.S. counternarcotics and security efforts: eradication of coca, interdiction of cocaine, security and rule of law, and development.
Feb 11, 2022
Journal Article
Insights Into Mixing Fentanyl and Benzodiazepines From Canadian Drug Seizures
In 2020, there were 60,000 overdose deaths involving synthetic opioids in the US, where data lags and limited cross-agency coordination impedes understanding of transitioning illicit drug markets. Better data from Canada can offer some understanding.
Jan 25, 2022
News Release
Opioid Prescribing Declines, but Cuts Are Not Uniform Across Locations, Age Groups, or Type of Prescriber
The volume of prescription opioids dispensed from retail pharmacies declined by 21 percent from 2008 to 2018, but the decline was not uniform across geographic areas, among types of patients, or by type of prescriber.
Dec 27, 2021
Commentary
Green Light for Cannabis Legalisation in Germany Is Not a Clear-Cut Decision
The new “traffic light” coalition in Germany recently agreed to regulate the sale of cannabis to adults for recreational purposes in licensed shops. International experience has shown that great care is needed in how cannabis policy is shaped.
Dec 6, 2021
Journal Article
Origins of the Opioid Crisis and Its Enduring Impacts
In this paper, we examine the role of the 1996 introduction and marketing of OxyContin as a potential leading cause of the opioid crisis.
Oct 19, 2021

1
2
3
4
5
6
7
Next

Research conducted by

Researcher Spotlight

Mafalda Pardal

Research Leader and European lead for the RAND Drug Policy Research Center

Mafalda Pardal is a research leader at RAND Europe, working in the area of home affairs and social policy. Her research interests include the study of illicit markets, cannabis regulation and drug policy. She is also the European lead for the RAND Drug Policy Research Center.
Shann Hulme

Research Leader

Shann Hulme is research leader at RAND Europe whose research interests include drug policy, illicit markets, pharmaceutical diversion and non-medical use, family and domestic violence, and crime prevention.

Explore Our People »